Science Explorer Back to mapMap
Discussion
Company · Seongnam-si · South Korea

Genexine (South Korea)

genexine.comROR OpenAlex
Research works
32
▲ 15% vs 2018-21
Citations
790
25.0 per fractional work
Top-10% rate
8.7%
all institutions 10.0%
Open access
56%
world 40%
International
25%
world 18%
Genexine (South Korea)

Not ranked overall: Genexine (South Korea) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Genexine (South Korea) work in?

In all years, 51% of research at Genexine (South Korea) is in Life Sciences, 43% in Health Sciences. Its largest fields are Medicine (42%), Immunology and Microbiology (25%), Biochemistry, Genetics and Molecular Biology (23%). It does 2.5× the world's share of Life Sciences.

Life Sciences: 16 fractional works · 51.3% of its workImmunology and Microbiology: 8 fractional works · 25.3% of its workImmunology: 7 fractional works · 22.7% of its workMicrobiology: 1 fractional works · 1.6% of its workVirology: 0 fractional works · 1.0% of its workBiochemistry, Genetics and Molecular Biology: 7 fractional works · 23.0% of its workMolecular Biology: 5 fractional works · 16.3% of its workGenetics: 1 fractional works · 4.6% of its workBiotechnology: 0 fractional works · 1.1% of its workCell Biology: 0 fractional works · 0.6% of its workCancer Research: 0 fractional works · 0.4% of its workAgricultural and Biological Sciences: 1 fractional works · 2.9% of its workPlant Science: 0 fractional works · 1.2% of its workAgronomy and Crop Science: 0 fractional works · 0.6% of its workAnimal Science and Zoology: 0 fractional works · 0.5% of its workInsect Science: 0 fractional works · 0.5% of its workNeuroscience: 0 fractional works · 0.0% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.0% of its workHealth Sciences: 14 fractional works · 43.0% of its workMedicine: 13 fractional works · 41.6% of its workOncology: 4 fractional works · 11.9% of its workRadiology, Nuclear Medicine and Imaging: 2 fractional works · 4.8% of its workEpidemiology: 2 fractional works · 4.7% of its workPulmonary and Respiratory Medicine: 1 fractional works · 4.0% of its workInfectious Diseases: 1 fractional works · 2.3% of its workHematology: 0 fractional works · 1.6% of its workGenetics: 0 fractional works · 1.5% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 1.4% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 1.4% of its workRheumatology: 0 fractional works · 1.4% of its workPathology and Forensic Medicine: 0 fractional works · 1.3% of its workSurgery: 0 fractional works · 1.3% of its workNeurology: 0 fractional works · 0.9% of its workHepatology: 0 fractional works · 0.7% of its workRehabilitation: 0 fractional works · 0.5% of its workGastroenterology: 0 fractional works · 0.3% of its workImmunology and Allergy: 0 fractional works · 0.3% of its workOrthopedics and Sports Medicine: 0 fractional works · 0.3% of its workObstetrics and Gynecology: 0 fractional works · 0.3% of its workPhysiology: 0 fractional works · 0.3% of its workVeterinary: 0 fractional works · 1.0% of its workSmall Animals: 0 fractional works · 1.0% of its workNursing: 0 fractional works · 0.3% of its workNutrition and Dietetics: 0 fractional works · 0.3% of its workPhysical Sciences: 2 fractional works · 5.7% of its workEngineering: 1 fractional works · 2.5% of its workBiomedical Engineering: 1 fractional works · 1.7% of its workElectrical and Electronic Engineering: 0 fractional works · 0.8% of its workMaterials Science: 0 fractional works · 1.6% of its workBiomaterials: 0 fractional works · 1.0% of its workMaterials Chemistry: 0 fractional works · 0.5% of its workEnvironmental Science: 0 fractional works · 0.7% of its workWater Science and Technology: 0 fractional works · 0.7% of its workChemistry: 0 fractional works · 0.6% of its workPhysical and Theoretical Chemistry: 0 fractional works · 0.6% of its workChemical Engineering: 0 fractional works · 0.3% of its workFiltration and Separation: 0 fractional works · 0.3% of its workALL ITS WORKGenexine (SouthKorea)32fractional works, all years
Life Sciences51%Physical Sciences6%Health Sciences43%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 13 fields, with their numbers
    1. Immunology and Microbiology825.3%
    2. Biochemistry, Genetics and Molecular Biology723.0%
    3. Agricultural and Biological Sciences12.9%
    4. Neuroscience00.0%
    5. Pharmacology, Toxicology and Pharmaceutics00.0%
    1. Medicine1341.6%
    2. Veterinary01.0%
    3. Nursing00.3%
    1. Engineering12.5%
    2. Materials Science01.6%
    3. Environmental Science00.7%
    4. Chemistry00.6%
    5. Chemical Engineering00.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.90× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 4.88× its world share, 3 worksBiochemistry, Geneti…Immunology and Microbiology: 15.34× its world share, 2 worksImmunology and Micro…Neuroscience: 0.06× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 0.27× its world share, 0 worksPharmacology, Toxico…Chemistry: 1.09× its world share, 0 worksChemistryEngineering: 0.43× its world share, 1 worksEngineeringMedicine: 2.26× its world share, 4 worksMedicineVeterinary: 17.73× its world share, 0 worksVeterinary1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Veterinary, 17.7×. Every wedge is a field page.

All 9 fields, with their numbers
  1. Veterinary17.73×0 works
  2. Immunology and Microbiology15.34×2 works
  3. Biochemistry, Genetics and Molecular Biology4.88×3 works
  4. Medicine2.26×4 works
  5. Chemistry1.09×0 works
  6. Agricultural and Biological Sciences0.90×0 works
  7. Engineering0.43×1 works
  8. Pharmacology, Toxicology and Pharmaceutics0.27×0 works
  9. Neuroscience0.06×0 works

Who are the top researchers at Genexine (South Korea)?

Ranked on the quality score, Minkyu Heo lead among researchers whose main affiliation is Genexine (South Korea).

  1. 1 Minkyu Heo South Korea · #4,025,677 worldwide 126 citations · 17 works
All ranked researchers at Genexine (South Korea)

What are the most cited papers from Genexine (South Korea)?

The most cited paper from Genexine (South Korea) is "Cytoplasmic destruction of p53 by the endoplasmic reticulum‐resident ubiquitin ligase ‘Synoviolin’" (Satoshi Yamasaki et al., 2006), with 283 citations. Next come "Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients" (262) and "Multi-biofunction of antimicrobial peptide-immobilized silk fibroin nanofiber membrane: Implications for wound healing" (237).

Most cited papers
#PaperReleasedCitations
1 Cytoplasmic destruction of p53 by the endoplasmic reticulum‐resident ubiquitin ligase ‘Synoviolin’ Satoshi Yamasaki et al. · The EMBO Journal Open access 14 Dec 2006 283
2 Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients Tae Jin Kim et al. · Nature Communications Open access 30 Oct 2014 262
3 Multi-biofunction of antimicrobial peptide-immobilized silk fibroin nanofiber membrane: Implications for wound healing Dae Woong Song, Shin Hwan Kim, Hyung Hwan Kim et al. · Acta Biomaterialia 7 May 2016 237
4 Adsorption of divalent metal ions by succinylated and oxidized corn starches Dong-Keon Kweon, Jung-Weon Choi, E.-K Kim et al. · Carbohydrate Polymers Oct 2001 214
5 Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial Jin Won Youn, Soo Young Hur, Jung Won Woo et al. · The Lancet Oncology 30 Nov 2020 175
All 83 most cited papers, with filters and sorting

Which keywords describe research at Genexine (South Korea)?

By fractional works in all years, weighted toward what it does more of than the world: Cancer Immunotherapy, Immunity, Antigen Presentation, Immunotherapy, Innate Immunity, Glycosylation, Dendritic Cells and Monoclonal Antibodies.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Cancer Immunotherapy4▲ 84×2 topics
  2. Immunity3▲ 30×5 topics
  3. Antigen Presentation3▲ 91×2 topics
  4. Epidemiology3▲ 2.2×15 topics
  5. Immunotherapy3▲ 14×10 topics
  6. Innate Immunity3▲ 26×3 topics
  7. Glycosylation3▲ 39×3 topics
  8. Dendritic Cells3▲ 72×2 topics
  9. Monoclonal Antibodies2▲ 55×3 topics
  10. Tumor Antigen2▲ 97×1 topic
  11. Vaccine Adjuvants2▲ 97×1 topic
  12. Therapeutic Antibodies2▲ 58×2 topics
  13. Cancer2▲ 5.2×11 topics
  14. Inflammation2▲ 2.9×13 topics
  15. Autoimmunity2▲ 26×2 topics
  16. Gene Therapy2▲ 19×3 topics
  17. Lymphoma2▲ 33×3 topics
  18. TGF-ß2▲ 30×2 topics
  19. Antibody Engineering2▲ 48×1 topic
  20. Fc Receptors2▲ 48×1 topic
  21. Tumor Regression2▲ 55×2 topics
  22. CD4+CD25+1▲ 61×1 topic
  23. Chemotherapy1▲ 6.4×3 topics
  24. Foxp31▲ 61×1 topic
  25. Leukemia1▲ 67×2 topics
  26. Monoclonal Antibody1▲ 66×2 topics
  27. CAR T Cells1▲ 91×1 topic
  28. Chimeric Antigen Receptor1▲ 91×1 topic
  29. NK Cell Recognition1▲ 36×1 topic
  30. Natural Killer Cells1▲ 36×1 topic
  31. Immune System1▲ 10×3 topics
  32. Targeted Therapy1▲ 16×3 topics
  33. ALK Inhibitors1▲ 57×1 topic
  34. Biopharmaceuticals1▲ 46×2 topics
  35. Breast Cancer1▲ 12×1 topic
  36. EGFR Mutations1▲ 57×1 topic
  37. Genomic Profiling1▲ 33×2 topics
  38. HER21▲ 106×1 topic
  39. Immunogenicity1▲ 61×2 topics
  40. Vaccine1▲ 7.9×6 topics

Which research topics does Genexine (South Korea) publish most on?

By volume in 2022-now: HER2/EGFR in Cancer Research, Lung Cancer Treatments and Mutations, Immunotherapy and Immune Responses and Monoclonal and Polyclonal Antibodies Research.

HER2/EGFR in Cancer Research: 1 fractional worksLung Cancer Treatments and Mutations: 1 fractional worksImmunotherapy and Immune Responses: 1 fractional worksMonoclonal and Polyclonal Antibodies Research: 0 fractional worksCancer Immunotherapy and Biomarkers: 0 fractional worksGlycosylation and Glycop…0Glycosylation and Glycoproteins Research: 0 fractional worksT-cell and B-cell Immunology: 0 fractional worksProtein Degradation and Inhibitors: 0 fractional worksHistone Deacetylase Inhibitors Research: 0 fractional worksBlood groups and transfusion: 0 fractional works
OncologyPulmonary and Respiratory MedicineImmunologyRadiology, Nuclear Medicine and Imaging2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 HER2/EGFR in Cancer Research Oncology 1 works
  2. 2 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 1 works
  3. 3 Immunotherapy and Immune Responses Immunology 1 works
  4. 4 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
  5. 5 Cancer Immunotherapy and Biomarkers Oncology 0 works
  6. 6 Glycosylation and Glycoproteins Research Molecular Biology 0 works
  7. 7 T-cell and B-cell Immunology Immunology 0 works
  8. 8 Protein Degradation and Inhibitors Molecular Biology 0 works
  9. 9 Histone Deacetylase Inhibitors Research Molecular Biology 0 works
  10. 10 Blood groups and transfusion Hematology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available55.6%not open44.4%

World: 40% of research is openly available.

with international co-authors25.2%domestic only74.8%

World: 18% is written across borders.

How has Genexine (South Korea)'s research output changed?

Output in 2022-2025 was 15% higher than in 2018-2021.

still counting20052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Genexine (South Korea) as a percentage of every work published that year, 0.000034% in 2024.

still counting0.000025%0.000050%0.000075%Genexine (South Korea)0.000059% in 202520102020

Fractional works of Genexine (South Korea) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Seongnam-si

All research institutions in Seongnam-si

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Genexine (South Korea). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.